Defense World
19 Jul 2026, 08:01 UTC · 16w ago
Impact · against what's priced in
The news for Corvus Pharmaceuticals is largely stale, as the primary drivers—a Goldman Sachs buy rating and insider buying—occurred months ago and are already reflected in the current price. Other mentions of Zura Bio and ADP provide no material fundamental updates.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish
Goldman Sachs initiated coverage of Corvus Pharmaceuticals with a 'buy' rating and a $40.00 price target.
More positive than 93% of claims this week
Director David Scott Moore acquired 21,700 shares of CRVS at an average price of $11.53 per share.
Continue reading
5 related stories
The mention of a position held by Copeland Capital Management is a routine disclosure of holdings and does not change the company's fundamentals.
Read from the article alone
No priced-in read yet
The cited Goldman Sachs 'buy' rating and $40 target were issued in April, and the insider purchase by David Scott Moore occurred in June; the market has had months to incorporate these events.
Read from the article alone
No priced-in read yet
The article merely notes a mid-day price increase without providing any fundamental reason or news.
Read from the article alone
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 76% of claims this week
Corvus Pharmaceuticals reported a quarterly EPS miss of ($0.15) against a consensus estimate of ($0.14).
More negative than 70% of claims this week
Wall Street Zen downgraded CRVS from 'hold' to 'sell' and Weiss Ratings lowered its rating to 'sell (e+)'.
So whatMultiple analyst downgrades to 'sell' put downward pressure on the stock price.
More negative than 70% of claims this week
Which stocks this story touches
More positive than 75% of ticker scores this week
The stock is trading 5.3% higher.
More positive than 65% of ticker scores this week
The stock is up 5.1% with a 'Moderate Buy' consensus, a high price target from Goldman Sachs, and significant insider/institutional buying, despite a slight earnings miss.
More positive than 54% of ticker scores this week
Mentioned as a positive position held by Copeland Capital Management LLC.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
42m ago
+18.6%
$302.67 vs $255.27 close before publication (Jul 17) · not market-adjusted
ADP chart →−25.0%
$4.09 vs $5.45 close before publication (Jul 17) · not market-adjusted
ZURA chart →−28.1%
$10.71 vs $14.90 close before publication (Jul 17) · not market-adjusted
CRVS chart →
